Ask a Mentor: On finding a niche in the field, developing a career in academics and better serving patients of color
We are excited to announce another installment of our new recurring series: Ask a Mentor. In this monthly segment, we will identify an accomplished mentor in the field of Dermatology to answer your questions about career development and their unique areas of expertise.
If you have questions on finding a niche in the field, developing a career in academics and/or better serving patients of color …
We are excited to announce another installment of our new recurring series: Ask a Mentor. In this monthly segment, we will identify an accomplished mentor in the field of Dermatology to answer your questions about career development and their unique areas of expertise.
If you have questions on finding a niche in the field, developing a career in academics and/or better serving patients of color … 
Which of the following is true about this condition?
A. Histology will show amastagotes in plasma cells.
B. Cuture is performed on MacConkey agar.
C. Diagnosis may be made by sending a sample
for real-time PCR assay to the Centers for Disease Control and Prevention.
D. This condition does not typically resolve without treatment.
E. Treatment for cutaneous and … 
An 80-year-old man with Parkinson’s disease developed a new pruritic eruption with these cutaneous findings. What is the antigenic target of the autoantibodies generated in this condition
A. NC16A of BPAg1
B. NC16A of BPAg2
C. C-terminal of BPAg1
D. C-terminal of BPAg2
E. alpha-6-beta-4 integrin
To find out the correct answer and read t … 
The last few years have seen no shortage of think pieces about how millennials are changing our world and our culture. From changes in social norms, to their embrace of technology to “killing” various industries, there’s a fascination with how this young generation (myself included) is leaving their mark on our society. There have also been several articles concerned with how our generat … 
This patient is not a candidate for systemic therapy and declines surgical treatment. Which of the following injectable agents is an oncolytic virus that is FDA-approved for inoperable disease?
A) Talimogene laherparepvec (T-VEC)
B) Interleukin-2
C) GM-CSF
D) Rose bengal
E) bacille Calmette-Guerin (BCG)
To find out the correct answer and …